Z-WEHD-FMK: Potent Irreversible Caspase-1/4/5 Inhibitor

Executive Summary: Z-WEHD-FMK, also known as Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK, is a highly selective, irreversible inhibitor of inflammatory caspases-1, -4, and -5, widely used in apoptosis and inflammation research (product_spec). It disrupts caspase-mediated proteolysis, including cleavage events crucial for pyroptosis and pathogen-induced cell remodeling (DOI). Z-WEHD-FMK effectively blocks Chlamydia-induced Golgi fragmentation at 80 μM in HeLa cells for 9 hours (product_spec). Its utility extends to modulating lipid trafficking and bacterial proliferation in infectious disease models. APExBIO supplies Z-WEHD-FMK under SKU A1924, with validated solubility and storage parameters for experimental reproducibility.

Biological Rationale

Inflammatory caspases, particularly caspase-1, -4, and -5, are essential for mediating pyroptosis and the maturation of pro-inflammatory cytokines. In canonical inflammasomes, caspase-1 is activated through oligomerization, leading to gasdermin D cleavage and cell lysis (DOI). Non-canonical pathways involve direct activation of caspase-4/5 by cytosolic lipopolysaccharide. Aberrant caspase activation is implicated in chronic inflammation, infectious disease progression, and cancer cell fate decisions. Therefore, precise inhibition of these caspases is critical for dissecting the roles of pyroptosis and apoptosis in health and disease (internal_link).

Mechanism of Action of Z-WEHD-FMK

Z-WEHD-FMK is a peptide-based, cell-permeable inhibitor designed to mimic the caspase substrate recognition motif. The FMK (fluoromethyl ketone) group forms a covalent, irreversible bond with the active site cysteine of target caspases, thereby blocking substrate cleavage (product_spec). It selectively inhibits caspase-1, -4, and -5, preventing the cleavage of downstream effectors such as gasdermin D and golgin-84. This inhibition halts the execution of pyroptosis and disrupts cellular events like Golgi fragmentation induced by intracellular pathogens (DOI).

Evidence & Benchmarks

• Z-WEHD-FMK at 80 μM for 9 hours prevents Chlamydia trachomatis-induced Golgi fragmentation in HeLa cells by inhibiting golgin-84 cleavage (product_spec).
• Caspase-1 inhibition blocks pyroptotic cell death in lung carcinoma models following HOXC8 knockdown, as confirmed by YVAD and analogous inhibitors (DOI).
• Z-WEHD-FMK dissolves in DMSO (≥46.33 mg/mL) and ethanol (≥26.32 mg/mL with sonication), but is insoluble in water (product_spec).
• Irreversible inhibition of caspase-1/4/5 using Z-WEHD-FMK enables reproducible dissection of caspase signaling in inflammation and apoptosis assays (internal_link).
• HOXC8 regulates caspase-1 expression; depletion of HOXC8 increases caspase-1 and pyroptosis, which is prevented by caspase-1 inhibitors (DOI).

This article extends previous summaries (internal_link) by providing updated evidence on infectious disease applications and solubility parameters, not covered in earlier reviews.

Applications, Limits & Misconceptions

Z-WEHD-FMK is widely used in inflammation research, apoptosis assays, and infectious disease research models. It is effective in blocking pyroptosis, dissecting the caspase signaling pathway, and studying pathogen-induced host cell modifications. However, its specificity is largely limited to caspase-1, -4, and -5; it does not inhibit other caspases or proteases outside this subgroup (product_spec).

For optimal results, Z-WEHD-FMK should be freshly prepared in DMSO or ethanol and stored at -20°C, as prolonged storage in solution can reduce activity (product_spec).

Common Pitfalls or Misconceptions

• Assuming Z-WEHD-FMK inhibits non-inflammatory caspases (e.g., caspase-3): it is highly selective for caspase-1/4/5 only (product_spec).
• Using Z-WEHD-FMK in aqueous solutions: the compound is insoluble in water, leading to precipitation and loss of activity.
• Long-term storage of prepared solutions: activity may decrease; use freshly prepared aliquots (product_spec).
• Overgeneralizing efficacy: blocking caspase-1/4/5 may not affect non-pyroptotic cell death pathways.
• Assuming all inflammatory cell death is pyroptosis: other forms (e.g., necroptosis) are not affected by Z-WEHD-FMK (DOI).

Workflow Integration & Parameters

Protocol Parameters

• Apoptosis/pyroptosis inhibition in HeLa cells | 80 μM, 9 hours | Chlamydia trachomatis infection studies | Prevents Golgi fragmentation and bacterial proliferation | product_spec
• Solubility | ≥46.33 mg/mL (DMSO), ≥26.32 mg/mL (ethanol, sonicated) | Stock preparation | Ensures maximal activity in cell assays | product_spec
• Storage | -20°C (dry), avoid long-term stock solution storage | All research | Preserves compound integrity | product_spec
• Pyroptosis inhibition in NSCLC cells | Use of caspase-1 inhibitors blocks HOXC8 knockdown-induced death | Cancer cell assays | Validates caspase-1 as mechanism | DOI

For advanced assay integration, refer to scenario-driven workflows (internal_link) for troubleshooting and optimization. This article clarifies the molecular rationale underlying the recommended concentrations.

Conclusion & Outlook

Z-WEHD-FMK remains a gold-standard, irreversible caspase-1/4/5 inhibitor for mechanistic studies of inflammation, apoptosis, and microbial pathogenesis. Its use has clarified the roles of caspase-driven pyroptosis and host-pathogen interactions, particularly in models such as Chlamydia-infected HeLa cells and HOXC8-knockdown NSCLC cells (DOI). APExBIO's Z-WEHD-FMK (SKU A1924) is recommended for precise, reproducible caspase inhibition in cell-based research. Future directions include further contextualizing caspase-1/4/5 inhibition in diverse disease models, as supported by recent peer-reviewed studies. No direct evidence supports cross-domain application beyond inflammation, apoptosis, and infectious disease as of latest verification.